GCC Reports Fourth Quarter and Full Year 2018 Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
36
GCC Reports Fourth Quarter and Full Year 2018 Results

CHIHUAHUA, Mexico, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Grupo Cementos de Chihuahua, S.A.B. de C.V. (BMV: GCC*) a leading producer of cement and ready-mix concrete in the United States and Mexico, today announces its results for the fourth quarter and full year of 2018.

4Q18 KEY HIGHLIGHTS

  • Consolidated Net Sales decreased 3.9% to US$ 205.9 million in 4Q18, mainly driven by lower cement and concrete volumes in the U.S.
  • EBITDA decreased 16.9% to US$ 57.4 million and EBITDA margin was 27.9%
  • Net leverage (Net debt/EBITDA) ratio decreased to 1.59x in December 2018 from 1.86x in December 2017
  • EBITDA to Free Cash Flow conversion was 79%
  • Successful full integration of the Trident Plant in Montana, onboarding proceeding well, and significant synergies have been identified
  • Completion of Rapid City plant expansion tie-in process, operational ramp up in progress
  • Oil well cement demand remains strong despite challenging environment

  FY18 KEY HIGHLIGHTS

  • Consolidated Net Sales increased 7.2% to US$ 883.2 million in FY18, mainly driven by higher sales volumes and prices in the U.S. and Mexico
  • EBITDA increased 6.7% to US$ 256.0 million. EBITDA margin contracted 10 basis points to 29.0%
  • EBITDA to Free Cash Flow conversion was 42%
  • Completion of a comprehensive new term loan agreement, replacing all existing bank debt while reducing interest expense with improved terms and conditions
  • S&P Global Ratings (S&P) long-term corporate rating raised to BB+ from BB, with a stable outlook. S&P also raised the rating on GCC’s senior unsecured notes due 2024 to BB+
  • GCC shares included within the Mexican Bolsa’s S&P/BMV IPC blue-chip index and within the MSCI family of stock indexes

Enrique Escalante , GCC’s Chief Executive Officer, commented : “We executed several transactions during 2018 which put GCC in a very solid position moving forward. We completed a purchase-sale transaction exchanging GCC’s ready-mix plants in Oklahoma and Northwest Arkansas, which were not integrated into our cement distribution network, for a cement plant in Montana representing a strategic addition to our system that will also improve our profitability. This plant, along with the completion of capacity expansion at our South Dakota cement plant in Rapid City, will enable us to continue to benefit from the robust pace of growth in the U.S. economy. Additionally, we further strengthened our balance sheet with a very efficient debt refinancing executed ahead of the Presidential elections in Mexico and which significantly improves our amortization schedule.

Despite the many challenges we experienced throughout the year, we delivered both strong operational results for 2018 and received positive customer feedback. While the one-time effect of our Rapid City tie-in delay adversely impacted fourth quarter results, this was resolved, and the operational ramp up is ongoing. Importantly, moving forward, GCC’s Rapid City plant will provide considerable benefits, addressing our prior capacity deficit with reduced logistics and production costs while enabling us to identify and service new customers without our prior limitations.”

“We are on the path of operational and financial transformation, as is evidenced by our recently announced Fitch upgrade from BB to BB+ with a stable outlook; further, over the past five years GCC has delivered 860 basis points of EBITDA margin expansion and we remain committed to achieving our long-term goals.”

Mr. Escalante continued, “GCC’s strong balance sheet and a robust free cash flow generation today make GCC one of the best positioned companies in the industry to capitalize on the growing U.S. economy, weather a challenging environment or act on potential strategic acquisitions aligned with our strict criteria that these be well-priced, complementary, integrated and value added.”

KEY FIGURES (millions of dollars)

  4Q18 4Q17 4Q18 vs. 4Q17 2018 2017 2018 vs. 2017
Net Sales 205.9 214.2 -3.9% 883.2 824.1 7.2%
Operating Income before other expenses 28.8 49.3 -41.6% 169.5 160.8 5.4%
EBITDA* 57.4 69.0 -16.9% 256.0 239.8 6.7%
EBITDA margin 27.9% 32.2%   29.0% 29.1%  
Free Cash Flow** 45.3 66.7 -32.1% 107.7 111.6 -3.5%
Income from continuing operations 21.3 27.8 -23.5% 104.5 78.7 32.7%
Discontinued operations 0.01 1.1   (41.0) 5.0  
Net Income 21.3 28.9 -26.4% 63.5 83.7 -24.2%
Earnings per Share (US$)*** 0.0641 0.0870   0.1909 0.2517  

*EBITDA: operating income before other expenses + depreciation and amortization.  **Free Cash flow before expansion CAPEX  ***Earnings per share calculated based on average number of outstanding shares during the quarter

OUTLOOK FOR 2019

2019 Outlook    
United States  
Volumes Cement  4% -6%
  Cement, like-to-like  2% - 3%
  Concrete  6% - 8%
Prices (US$)    
  Cement 4% - 5%
  Concrete  2%  -4%
Mexico  
Volumes Cement =
  Concrete =
Prices (Ps.) Cement 3% - 5%
  Concrete 3% - 5%
     
Consolidated    
EBITDA Growth    20% - 23%
EBITDA Growth without IFRS-16   12%- 15%
FCF Conversion Rate *   > 50%
Working Capital   Slight decrease
Total CapEx   US$ 70 million
  Maintenance $60
  2018 carry- over $10
Net Debt / EBITDA, end -year < 1x

*Free Cash Flow conversion rate: free cash flow after Maintenance capex/EBITDA

EARNINGS REPORT

GCC’s fourth quarter and full year 2018 earnings report is available at www.gcc.com , on the Investor Relations page.

CONFERENCE CALL

Grupo Cementos de Chihuahua, S.A.B. de C.V. will host its earnings conference call on February 14, 2019. 

Time:      11:00 pm (Eastern Time) / 10:00 pm (Mexico City) / 09:00 pm (Mountain Time) 

Conference ID: 8208114

Dial in:    

U.S.:                                (866) 575 6539 Toll Free

International:                   +1 (323) 994 2082

Replay (through February 21, 2019):

               U.S.:                                    (844) 512 2921 Toll Free

               International:                       +1 (412) 317 6671

Listen-only webcast and replay:  click here .

ABOUT GCC

GCC is a leading supplier of cement, concrete, aggregates, and construction‐related services in the United States and Mexico, with an annual cement production capacity of 5.8 million metric tons. Founded in 1941, the Company’s shares are listed on the Mexican Stock Exchange under the ticker symbol GCC*. GCC is included in the MSCI family of indexes and the benchmark S&P/BMV IPC index of Mexican stocks.

Forward Looking Statements

This press release may contain forward-looking statements. All statements that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “expect,” “estimate,” “intend,” “project” and similar expressions are generally intended to identify forward-looking statements. These statements are subject to risks and uncertainties including, among others, changes in macroeconomic, political, governmental or business conditions in the markets where GCC operates; changes in interest rates, inflation rates and currency exchange rates; performance of the construction industry; pricing, business strategy, and other factors. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from the beliefs, projections, and estimates described herein. GCC assumes no obligation to update the information contained in this press release.

For further information, contact:

GCC Investor Relations:
Ricardo Martinez +52 (614) 442 3176 + 1 (303) 739 5943 rmartinezg@gcc.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 119

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 50

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 612

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 56

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 351

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 84

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

Equitage Ventures Launches $47.3M Fund for Senior Care Tech

Updated Category News Views 329

Equitage Ventures Launches Significant Investment Fund Equitage Ventures, an early-stage venture capital firm dedicated to AgeTech, has announced the successful final closing of a substantial $47.3 million investment fund. This fund is designed to provide critical capital, distribution resources, and strategic guidance to innovative entrepreneurs who aim to tackle the...

Continue Reading
Understanding Market Trends: Insights into Chevron Corp's Performance

Updated Category News Views 171

Chevron Corp Market Sentiment Analysis Chevron Corp (NYSE: CVX) has experienced a noteworthy decline in its short interest as a percentage of float, showing a 10.26% decrease since its previous report. Currently, there are approximately 14.02 million shares sold short, which accounts for 0.7% of all shares available for trading. Given the trading volume, it is estimated...

Continue Reading
Establishment of Blakely McCrory Hope Fund at Moody Gardens

Updated Category News Views 200

Introducing the Blakely McCrory Hope Fund Moody Gardens is proud to announce a special initiative to honor the memory of a young girl who captured the hearts of many: the Blakely McCrory Hope Fund. This fund has been established in loving memory of 8-year-old Blakely McCrory, who lost her life in a tragic flooding incident that occurred during the summer months....

Continue Reading
Star-Studded Table Read of 'It's a Wonderful Life' Event

Updated Category News Views 221

Exciting Holiday Table Read for a Worthy Cause The Ed Asner Family Center is pulling out all the stops this holiday season with an exciting virtual table read of the beloved classic, "It's a Wonderful Life." Scheduled for December 14 at 5 PM PST, this event promises to spread joy while supporting individuals and families with special needs. Star-Studded Cast Comes...

Continue Reading
Transforming $100 Into Over $1700 with Monolithic Power Systems

Updated Category News Views 145

Understanding the Growth of Monolithic Power Systems Monolithic Power Systems (NASDAQ: MPWR) has showcased impressive financial performance over the past decade, outperforming many market benchmarks. With an impressive annualized growth rate of 19.88%, it has attracted the attention of savvy investors. The Power of Compounded Returns Imagine investing $100 in MPWR stock...

Continue Reading